16:40 EST Arcus Biosciences (RCUS) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Buy Rating on Arcus Biosciences Driven by Best-in-Class Casdatifan Data in Renal Cell Carcinoma and Favorable Phase 3 Risk‑Reward
- Arcus’s Lead HIF-2α Inhibitor Delivers Superior Late-Line RCC Efficacy, De-Risking PEAK-1 and Supporting Buy Rating
- Arcus Biosciences’ casdatifan shows increased survival in kidney cancer
- Arcus Biosciences (RCUS) Q4 Earnings Cheat Sheet
- Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo